Pan-JAK

Class

Topical soft pan-JAK inhibitor

Janus kinases (JAK1, JAK2, JAK3, and TYK2) are enzymes that sit just inside the cell membrane, attached to receptors for cytokines—signaling proteins that coordinate immune responses. When a cytokine binds its receptor, associated JAK enzymes activate, adding phosphate groups to intracellular proteins called STATs, which then travel to the nucleus and switch on genes involved in inflammation and immune cell activity. A 'pan-JAK' inhibitor blocks all four family members rather than a single subtype, providing broad suppression of cytokine signaling because many inflammatory skin conditions are driven by multiple, overlapping cytokine pathways rather than just one. Restricting this inhibition to the skin, through a topical 'soft drug' design—meaning the compound is built to break down quickly once absorbed into the bloodstream—aims to dampen local inflammation while limiting exposure of the rest of the body to JAK blockade, since systemic JAK inhibition can affect blood cell production and broader immune defense. This mechanism is broadly relevant to inflammatory and immune-mediated dermatologic conditions, including eczema-type and psoriatic disorders, where cytokine-driven JAK-STAT signaling in skin cells contributes to redness, itching, and tissue changes.